GAME OVER: " Lyme/Relapsing Fever is a permanent, incurable infection " (Mouse Infectivity Test Performed)
Mort Zuckerman
Durlan...@yale.edu, Aa...@columbia.edu, gary_w...@nymc.edu,
scientifi...@ostp.gov, pkru...@princeton.edu,
Stanle...@fiu.edu, emcsw...@niaid.nih.gov, afa...@niaid.nih.gov,
Spin...@yahoogroups.com, kshe...@calea.org, fit...@gmail.com,
patrick.f...@usdoj.gov, model...@sbcglobal.net,
jdr...@nejm.org, let...@courant.com, Jgerb...@cdc.gov,
michae...@po.state.ct.us, con...@po.state.ct.us, executive-
edi...@nytimes.com, managin...@nytimes.com, news-
ti...@nytimes.com, biz...@nytimes.com, for...@nytimes.com,
nati...@nytimes.com, dv...@cdc.gov, brigidc...@optonline.net,
tr...@hotmail.com, illino...@aol.com, jle...@courant.com,
tinaj...@yahoo.com, jhorn...@fff.org, thomas...@usdoj.gov,
thoma...@po.state.ct.us, kur...@washpost.com,
georg...@washpost.com, p...@allegorypress.com,
commissi...@po.state.ct.us, brans...@comcast.net,
vts...@comcast.net, o...@po.state.ct.us, freet...@charter.net,
scott....@po.state.ct.us, govern...@po.state.ct.us,
attorney...@po.state.ct.us, randall...@usdoj.gov,
Robert....@yale.edu, edi...@greenwich-post.com,
harol...@yale.edu, sedm...@nswbc.org, rrmcg...@aol.com,
fr...@nytimes.com, dpr...@stmartin.edu
Cc: fra...@ucia.gov, dr-ahma...@president.ir,
eugener...@washpost.com, afa...@niaid.nih.gov,
bmi...@newstimes.com, tr...@hotmail.com, rast...@aol.com,
billc...@gmail.com, amcg...@rms-law.com, rjmu...@aol.com,
paulcrai...@yahoo.com, sidney_b...@yahoo.com,
criminal...@usdoj.gov, karla.d...@usdoj.gov,
christophe...@usdoj.gov, richar...@yale.edu,
harol...@yale.edu, james.p...@yale.edu, inq...@aldf.com,
ly...@idsociety.org, meganm...@theatlantic.com
Subject: GAME OVER: " Lyme/Relapsing Fever is a permanent, incurable
infection " (Mouse Infectivity Test Performed)
Date: Jan 27, 2010 11:38 AM
Even when playing with only the
funky OspA gene.
Antimicrob Agents Chemother. 2010 Feb;54(2):643-51. Epub 2009 Dec 7.
Ineffectiveness of Tigecycline against Persistent Borrelia
burgdorferi.
Barthold SW, Hodzic E, Imai DM, Feng S, Yang X, Luft BJ.
Center for Comparative Medicine, Schools of Medicine and Veterinary
Medicine, University of California at Davis, One Shields Avenue,
Davis, CA 95616. swbar...@ucdavis.edu.
The effectiveness of a new first-in-class antibiotic, tigecycline
(glycylcycline), was evaluated during the early dissemination (1
week), early immune (3 weeks), or late persistent (4 months) phases of
Borrelia burgdorferi infection in C3H mice. Mice were treated with
high or low doses of tigecycline, saline (negative-effect controls),
or a previously published regimen of ceftriaxone (positive-effect
controls). Infection status was assessed at 3 months after treatment
by culture, quantitative ospA real-time PCR, and subcutaneous
transplantation of joint and heart tissue into SCID mice. Tissues from
all saline-treated mice were culture and ospA PCR positive, tissues
from all antibiotic-treated mice were culture negative, and some of
the tissues from most of the mice treated with antibiotics were ospA
PCR positive, although the DNA marker load was markedly decreased
compared to that in saline-treated mice. Antibiotic treatment during
the early stage of infection appeared to be more effective than
treatment that began during later stages of infection. The viability
of noncultivable spirochetes in antibiotic-treated mice (demonstrable
by PCR) was confirmed by transplantation of tissue allografts from
treated mice into SCID mice, with dissemination of spirochetal DNA to
multiple recipient tissues, and by xenodiagnosis, including
acquisition by ticks, transmission by ticks to SCID mice, and survival
through molting into nymphs and then into adults. Furthermore, PCR-
positive heart base tissue from antibiotic-treated mice revealed RNA
transcription of several B. burgdorferi genes. These results extended
previous studies with ceftriaxone, indicating that antibiotic
treatment is unable to clear persisting spirochetes, which remain
viable and infectious, but are nondividing or slowly dividing.
"[Real] scientists are *fiercely* independent. That's the good
news."-- NIH's Top Fool, Anthony Fauci